Ligand Pharmaceuticals to Acquire XOMA Royalty for $739M, Boosting EPS and Diversifying Portfolio
LGND has more than doubled off its 52-week low of $98.89.
Summary
Ligand Pharmaceuticals will acquire XOMA Royalty Corporation for $739 million in cash and CVRs, a move expected to immediately boost Ligand's EPS and significantly expand its biopharma royalty portfolio.
Key Events · M&A and Partnerships · LGND
-
Definitive Acquisition Agreement
Ligand Pharmaceuticals will acquire XOMA Royalty Corporation for approximately $739 million, comprising $39.00 per share in cash and one non-transferable Contingent Value Right (CVR) per share. The transaction is expected to close in Q3 2026.
-
Significant Portfolio Expansion
The acquisition adds seven new commercial products and over 100 development-stage assets, nearly doubling Ligand's royalty portfolio and enhancing diversification across therapeutic areas.
-
Positive Financial Impact & Raised Guidance
The transaction is expected to be immediately accretive to Ligand's adjusted EPS, with 2026 guidance raised to $8.50-$9.50 and a projected $1.50 per share accretion in 2027.
-
Shareholder Support Secured
Key XOMA Royalty shareholders, including BVF Partners (representing approximately 47% of outstanding shares), have entered into voting agreements in favor of the transaction, increasing the likelihood of approval.
Analysis · LGND · Life Sciences
Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million, consisting of $39.00 per share in cash and one non-transferable Contingent Value Right (CVR) per share. This strategic acquisition, which follows a news announcement earlier today, is expected to be immediately accretive to Ligand's adjusted EPS, with 2026 guidance raised to $8.50-$9.50 and a projected $1.50 per share accretion in 2027. The deal significantly expands Ligand's royalty portfolio by adding seven new commercial products and over 100 development-stage assets, enhancing long-term growth and diversification. The transaction is further solidified by voting agreements from major XOMA Royalty shareholders, including BVF Partners, representing approximately 47% of outstanding shares, which increases the certainty of shareholder approval.
At the time of this filing, LGND was trading at $240.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $98.89 to $247.38. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.